DNA adducts from chemotherapeutic agents

Area of Science:

• * Molecular Biology
• * Cancer Research
• * Pharmacology

Background:

• * Early hypothesis: anti-cancer alkylating drugs cross-link essential macromolecules for cell division.
• * DNA identified as the primary target; mustard gas and platinum drugs form DNA cross-links.
• * Single DNA cross-links can be lethal, especially in repair-deficient cells.

Purpose of the Study:

• * To investigate the relationship between DNA alkylation extent and therapeutic outcome in cancer patients.
• * To compare DNA alkylation levels in tumor cells versus normal cells.
• * To explore strategies for enhancing DNA alkylation in target tumor DNA.

Main Methods:

• * Immunoassays to measure DNA alkylation in peripheral blood leukocytes and tumor cells of patients treated with chemotherapeutic drugs.
• * Quantitative correlations between DNA alkylation and cellular inactivation.
• * Comparative studies using bacteriophage, bacteria, and cultured mammalian cells.

Main Results:

• * Cultured mammalian cells tolerate hundreds of DNA cross-links; repair mechanisms are crucial.
• * DNA alkylation levels in patients' leukocytes often near or below mean lethal doses for normal cells.
• * Some patients show significant DNA alkylation in tumors, correlating with favorable outcomes, but often insufficient for lethality.
• * Variability in individual responses and adduct levels observed, suggesting a pharmacogenetic basis.

Conclusions:

• * Effective chemotherapy requires higher extents of DNA alkylation in tumor cells than typically achieved.
• * Current drug doses may not reach therapeutically effective levels in all patients.
• * Strategies like higher dosing with bone marrow rescue or tumor-specific prodrug activation are needed to improve chemotherapy efficacy.